Media coverage about Eleven Biotherapeutics (NASDAQ:EBIO) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eleven Biotherapeutics earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.7541207625438 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of analysts have recently issued reports on the company. HC Wainwright started coverage on Eleven Biotherapeutics in a report on Tuesday, March 20th. They set a “buy” rating and a $2.00 target price for the company. ValuEngine raised Eleven Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Laidlaw started coverage on Eleven Biotherapeutics in a research report on Thursday, May 10th. They set a “buy” rating and a $8.00 price target on the stock.
Eleven Biotherapeutics stock traded up $0.64 during midday trading on Wednesday, hitting $3.29. 15,575,300 shares of the company were exchanged, compared to its average volume of 2,864,343. The firm has a market capitalization of $159.20 million, a PE ratio of -2.96 and a beta of 2.75. Eleven Biotherapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $3.50.
Eleven Biotherapeutics (NASDAQ:EBIO) last released its quarterly earnings results on Tuesday, May 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. sell-side analysts anticipate that Eleven Biotherapeutics will post -0.52 earnings per share for the current year.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc, a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.